Litcius/Paper detail

Bispecific antibodies targeting mutant<i>RAS</i>neoantigens

Jacqueline Douglass, Emily Han-Chung Hsiue, Brian J. Mog, Michael S. Hwang, Sarah R. DiNapoli, Alexander H. Pearlman, Michelle S. Miller, Katharine M. Wright, P. Aitana Azurmendi, Qing Wang, Suman Paul, A. Schaefer, Andrew D. Skora, Marco Dal Molin, Maximilian F. Konig, Qiang Liu, Evangeline Watson, Yana Li, Michael Murphy, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou

2021Science Immunology167 citationsDOIOpen Access PDF

Abstract

genes provided strong genetic evidence for the specificity of the scDbs. Thus, this approach could be applied to other common oncogenic mutations that are difficult to target by conventional means, allowing for more specific anticancer therapeutics.

Topics & Concepts

Phage displayAntibodyMutantBiologyAntigenContext (archaeology)Human leukocyte antigenMolecular biologyAlleleMutationCancer researchGeneGeneticsPaleontologyMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchT-cell and B-cell Immunology
Bispecific antibodies targeting mutant<i>RAS</i>neoantigens | Litcius